ABSTRACT
OBJECTIVE: To compare the efficacy and safety of a combination therapy, doxazosin plus tenoxicam, and doxazosin alone for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), as various combination therapies increase the efficacy of medical therapy. Alpha blocker agents have been widely used for the treatment of LUTS secondary to BPH. METHOD: Fifty-seven patients complaining of LUTS secondary to BPH were enrolled in this clinical trial. Patients were randomly assigned to receive doxazosin 4 mg or doxazosin 4 mg plus tenoxicam 20 mg treatment. Patients were evaluated for BPH according to the European Association of Urology and American Urological Association clinical guidelines. In addition, patients were assessed with Overactive Bladder Symptom Score (OABSS) and International Index of Erectile Function (IIEF). Patients were reevaluated after a 6-week treatment course. The International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Q(max)), and average urinary flow rates (AFR) were determined at baseline and again at 6 weeks as efficacy parameters. RESULTS: The total IPSS, IPSS-QoL, and OABSS decreased significantly in both tenoxicam plus doxazosin group and doxazosin alone group compared with baseline (P < .01). Also, Q(max) and AFR significantly improved in both groups (P < .01). The improvements in IPSS, IPSS-QoL, and OABSS were significantly better in patients treated with combination therapy (P < .05). CONCLUSIONS: COX-2 inhibitors in combination with an alpha blocker may increase the effectiveness of the therapy for LUTS secondary to BPH without significant effects on side effect profile.
Subject(s)
Adrenergic alpha-Antagonists/administration & dosage , Cyclooxygenase 2 Inhibitors/administration & dosage , Doxazosin/administration & dosage , Piroxicam/analogs & derivatives , Prostatic Hyperplasia/complications , Urination Disorders/drug therapy , Adrenergic alpha-Antagonists/adverse effects , Cyclooxygenase 2 Inhibitors/adverse effects , Doxazosin/adverse effects , Drug Therapy, Combination , Humans , Male , Middle Aged , Piroxicam/administration & dosage , Piroxicam/adverse effects , Urination Disorders/etiology , Urination Disorders/physiopathology , UrodynamicsABSTRACT
OBJECTIVE: To assess the effect of sildenafil citrate treatment on visual field analysis (VFA) in patients using sildenafil citrate for erectile dysfunction. MATERIALS AND METHODS: In this prospective study on 18 male volunteers with erectile dysfunction, bilateral VFA was performed using the Humphrey 30-2 central standard threshold test. White-on-white (W/W) and blue-on-yellow (B/Y) protocols were used prior to treatment (baseline VFA) and after treatment (repeat VFA) with sildenafil citrate. W/W and B/Y baseline VFA and repeat VFA mean deviations (MD) were compared. RESULTS: The baseline MD for W/W and B/Y protocols were -1.34 +/- 1.8 and -2.59 +/- 2.1 dB, respectively, whereas the mean repeat MD for W/W and B/Y protocols were -1.79 +/- 2.21 and -2.83 +/- 3.31 dB, respectively. There was no statistically significant difference between W/W and B/Y baseline and repeat VFA with respect to MD (p > 0.05). CONCLUSION: Sildenafil citrate causes no significant changes in Humphrey VFA in patients with erectile dysfunction.
